Cenix BioScience announced this week that it has signed multi-year deal to use its RNAi screening technology to discover novel drug targets for respiratory and inflammatory disease for AstraZeneca.
According to Cenix, the deal expands upon the companies' existing research arrangement in oncology, which was signed in 2008 (see GenomeWeb Daily News, 3/19/2008).
Under the new deal, Cenix will complete at least three projects for AstraZeneca that combine "multi-pass genome-scale screens for the discovery of novel [respiratory and inflammatory disease] target candidates with detailed validation analyses … using a number of primary human cell types," the company said.
Cenix will also adapt assays developed by AstraZeneca scientists to optimize their use in high-throughput RNAi studies in 384-well and/or 1,536-well formats.
Financial terms of the deal were not disclosed.